This article first appeared on GuruFocus .
-
Revenue:$874 million, up 8.7% reported and 11.9% organically; price contributed just over 4 percentage points of growth.
-
Adjusted EPS:$2.66, up 36% year over year and $0.47 above the midpoint of prior guidance.
-
Gross Margin:39.7%, up 310 basis points year over year on favorable HVP mix and price.
-
Adjusted Operating Margin:25.3%, up 420 basis points year over year on gross margin expansion and SG&A leverage.
-
Proprietary Products Segment:16.6% organic growth.
-
HVP Components Revenue:$467 million, up 20% organically; now 53% of total company revenues; non-GLP-1 HVP grew high teens; GLP-1 HVP grew well into the 30s and represented just under 12% of total revenues.
-
HVP Delivery Devices Revenue:$99 million, flat reported and up 26% organically excluding FX and SmartDose 3.5 divestiture.
-
Standard Products Revenue:$163 million, up 3% organically.
-
West Vantage Segment Revenue:$146 million, down 6.6% organically, better than expected.
-
SmartDose 3.5 Revenue:$12 million in Q3; $100 million for the year ($46 million Q1, $42 million Q2, $12 million Q3); expected ~290-basis-point headwind to reported growth next year.
-
Geographic Growth:Asia Pacific (11% of total revenues) up 42%; Americas up 12%; EMEA up 6%.
-
Free Cash Flow:$278 million for first nine months, down roughly 5% year over year.
-
Capital Expenditures:$125 million for first nine months; full-year CapEx expected at $215 million to $220 million.
-
Shareholder Returns:$47 million in dividends paid year to date; 34th consecutive annual dividend increase with an 18% raise; 2.4 million shares repurchased for $685 million.
-
Full-Year 2026 Revenue Guidance:$3.41 billion to $3.42 billion; organic sales growth of 11.3% to 11.6%; FX benefit of 120 basis points; SmartDose 3.5 divestiture a 160-basis-point headwind.
-
Q4 2026 Revenue Guidance:$820 million to $830 million, representing 6% to 7% organic growth.
-
Full-Year 2026 Adjusted EPS Guidance:$9.38 to $9.48, representing 29% to 30% year-over-year growth.
-
Full-Year 2026 Operating Margin:Expected to expand almost 300 basis points.
Release Date: October 29, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Q3 2026 revenues of $874 million grew 12% organically, exceeding expectations.
-
Adjusted EPS of $2.66 increased 36% year-over-year, beating guidance by $0.47.
-
HVP Components revenue grew 20% organically, driven by GLP-1 and non-GLP-1 demand and HVP upgrades.
-
Full-year 2026 revenue guidance raised to $3.41-$3.42 billion, with organic growth of 11.3%-11.6%.
-
Adjusted operating margin expanded 420 basis points to 25.3%, driven by gross margin expansion and SG&A leverage.
Negative Points
-
West Vantage segment revenues declined 6.6% organically due to legacy program roll-offs and CGM program decline.
-
SmartDose 3.5 divestiture will create a ~290 basis point headwind to reported growth in 2027.
-
Free cash flow for the first nine months decreased 5% year-over-year due to higher accounts receivable and inventory levels.
-
HVP Delivery Devices growth may be lumpy; Q4 growth is not expected to match Q3's strong performance.
-
GLP-1 revenue growth faces tougher comparisons ahead, with potential deceleration from high growth rates.
Q & A Highlights
Q: Doug Schenkel (UBS) asked about West's M&A criteria and whether ~10% is still the right planning assumption for GLP-1 revenue going forward, given year-to-date GLP-1 growth of over 30% against a tough comp. A: CEO Michel Lagarde said the organic profile is so strongmultiple secular tailwinds, an enviable market position, and a capable teamthat the first focus will always be strengthening organic prospects. Customers want supply chain simplification and supplier consolidation, and West is on their short list of preferred partners, but given its financial profile and organic prospects, the bar for M&A is incredibly high, allowing patience and discipline to pursue only deals that amplify the financial profile. On GLP-1, he remains incredibly bullish on the therapy class's full prospects, with opportunities to participate broadly across current players, new market entrants, new molecules, and biosimilar/generic players.
Q: Daniel Markowitz (Evercore ISI) asked for the moving pieces behind the record GLP-1 elastomers quarterMedicare Bridge program, OUS generics, and potential mix shift to multi-doseand whether anything was one-time in Q3, plus the growth outlook into 2027. A: CEO Michel Lagarde said the class of medicines continues to prove transformative and West is still early in its full potential, with geographies at different maturity levels, making it a durable multi-year growth driver with nothing one-off in the quarter. CFO Bob McMahon added there were no one-time items, the Bridge program is increasing access, OUS generics present opportunities in various markets, and next-generation molecules offer further upside down the road.
Q: Justin Bowers (Deutsche Bank) asked the new CEO to discuss his priorities over the next 6 to 12 months and opportunities to fortify West's moat. A: CEO Michel Lagarde cited the mission-driven, technically deep team as a towering strength built over 100 years. His priorities are forging closer, more strategic customer relationshipscurrently mostly at the operational/technical levelto gain better insights, enable joint demand planning, and speed innovation adoption, plus strengthening continuous improvement by raising ambitions and using digitization and automation to drive more impact across sites and global functions.
Q: Lawrence Solow (CJS Securities) asked whether the strong Q3 margins represent a new floor, and whether mid-40s% on the proprietary side is a good starting point for growth. A: CFO Bob McMahon said it is not a new floor but expressed optimism about continued margin expansion, noting no one-timers in Q3 and that the mix shift in HVP plus above-expectation growth demonstrated incremental margin strength. The 300 bps gross margin gain came from positive mix, leveraging the existing base, and price, with SG&A leverage below the line; the SmartDose divestiture will help going forward, and continuous improvement is an underappreciated opportunity for further margin expansion over the next several years.
Q: David Windley (Jefferies) asked whether West can drive efficiency into its footprint to meet demand with efficient CapEx, or whether a multi-year elevated CapEx regime is ahead. A: CEO Michel Lagarde said West is comfortable with the 6% to 8% of revenue range, sometimes at the low end and sometimes the high end, but not outside it. Continuous improvement will focus on de-bottlenecking and increasing output from current capacity, alongside the next wave of finishing capacity investment. CFO Bob McMahon added that West has been more thoughtful about capital priorities, disproportionately investing in highest-return HVP areas, doing tech transfers to level-load facilities and provide multiple sources, and noting finishing upgrades carry higher ROI without requiring more units.
Q: Sayle Moona (Barclays) asked how the HHS draft guidance similar to Annex 1 could affect the U.S. market, and for an update on drug handling progress versus expectations. A: CEO Michel Lagarde said global regulators often follow one anotherEurope's Annex 1 addressed contamination in manufacturing, not geographyso it is logical for U.S. regulators to focus on the same problem, and customers treat HVP upgrades as a global rather than regional strategy, making broader regulatory pressure a secular long-term growth trend. CFO Bob McMahon added most upgrades to date have been European-based, but new project pipelines increasingly include other geographies, a multi-year opportunity. On drug handling, Lagarde said West Vantage is progressing as expected, ramping higher-value-added contracts with a good opportunity funnel while legacy projects roll off, muting growth this year and next.
Q: Matt Larew (William Blair) asked whether strong HVP Delivery Devices growth ex-SmartDose is tied to a particular drug launch or new customer wins, or reflects a broadening opportunity set. A: CFO Bob McMahon said growth is not indicative of any one launch or molecule, with Crystal Zenith and Admin Systems broad-based across customers and markets. He cautioned that Q4 could be lumpy given a very strong prior-year Q4, so Q3-level growth is not expected to repeat, but West continues working with partners on the next-generation SmartDose 10 self-injection system and feels good about the portfolio.
Q: Paul Knight (KeyBanc) asked about the dynamics behind Asia Pacific's spectacular 42% growth. A: CEO Michel Lagarde noted the small base and new customer opportunities, calling it a great contributor to growth. CFO Bob McMahon added West has now posted three consecutive quarters of very strong Asia Pacific growth, driven by India and China across multiple markets including GLP-1 introductions, with a bigger longer-term opportunity as innovative drugs are developed in Asia.
Q: Curtis Moiles (BNP Paribas) asked about the sustainability of biologics revenue growth (up 26% year to date) and whether the ~4% price contribution in Q3 should continue. A: CEO Michel Lagarde said the innovation pipeline is at all-time records both in overall compounds and in the percentage that are biologics, which must be delivered via injection, so biologics should remain a continued growth driver. On price, he said 2% to 3% remains the right long-term assumption, with this year running a little ahead due to the environment.
Q: Brendan Smith (TD Cowen) asked where HVP mixnow over 50% of revenuescould go over the next year, and how the 2026 exit run rate tracks versus the 7% to 9% long-range plan. AFor the complete transcript of the earnings call, please refer to the full earnings call transcript .
